Seller record · Telehealth service

Fifty 410

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The home, weight loss and pricing pages and the terms refer only to independent compounding pharmacies. 1 more criterion also fails; see the table below.

At a glance

Fifty 410Telehealth service

6/8criteria passed

Price: Semaglutide $199 a month, tirzepatide from $133 a month on a three-month program
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: 1 on file

Visit Fifty 410 See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and compounded tirzepatide, with payment requested only after a licensed provider reviews an online intake and prescribes. It lists hair care and longevity options as coming soon, and no pharmacy is named.

Operating entity Aspen Aesthetics, LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Fifty 410's website; Fifty 410's weight loss page
S2	Prescription gating	PASS	Fifty 410's website; Fifty 410's weight loss page; Fifty 410's semaglutide page
S3	Pharmacy identification	FAIL	Fifty 410's website; Fifty 410's weight loss page; Fifty 410's terms
S4	Compounding disclosure	PASS	Fifty 410's weight loss page; Fifty 410's semaglutide page
S5	Analytical documentation	FAIL	Fifty 410's weight loss page; Fifty 410's safety page; Fifty 410's terms
S6	Business address	PASS	Fifty 410's privacy page; Fifty 410's terms; Fifty 410's contact page
S7	Price disclosure	PASS	Fifty 410's pricing page; Fifty 410's semaglutide page; Fifty 410's tirzepatide page
S8	Enforcement status	PASS	FDA's website; FDA warning letter 721481

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed healthcare provider reviews each online intake through a patient appointment and makes every eligibility and prescribing decision, and the site says an intake never guarantees a prescription.Source: Fifty 410's website; Fifty 410's weight loss page.

S2PASSThe home and weight loss pages say no credit card is needed to start and that payment is requested only if a provider issues a prescription, and the pricing answers say a payment link is sent after a prescription is issued.Source: Fifty 410's website; Fifty 410's weight loss page; Fifty 410's semaglutide page.

S3FAILNo filling pharmacy is named. The home, weight loss and pricing pages and the terms refer only to independent compounding pharmacies.Source: Fifty 410's website; Fifty 410's weight loss page; Fifty 410's terms.

S4PASSThe weight loss and pricing pages state that compounded semaglutide and tirzepatide are not FDA-approved and that the FDA has not reviewed them for safety, effectiveness or quality.Source: Fifty 410's weight loss page; Fifty 410's semaglutide page.

S5FAILNo certificate of analysis or lot document is published on the weight loss, pricing or safety pages or in the terms.Source: Fifty 410's weight loss page; Fifty 410's safety page; Fifty 410's terms.

S6PASSAspen Aesthetics, LLC, doing business as Fifty 410 Health, at 1630 W Prosper Trail, Suite 620, Prosper, Texas 75078, printed in the privacy policy and the terms, with the same street address on the contact page. The terms name Texas law.Source: Fifty 410's privacy page; Fifty 410's terms; Fifty 410's contact page.

S7PASSCompounded semaglutide at $199 a month. Compounded tirzepatide on three-month programs at $399 ($133 a month), $499 ($166 a month) or $549 ($183 a month) by dose tier. Each program includes the provider consultation, the medication and refrigerated shipping, with no subscription.Source: Fifty 410's pricing page; Fifty 410's semaglutide page; Fifty 410's tirzepatide page.

S8PASSFDA warning letter 721481, February 2026, names Aspen Aesthetics doing business as Fifty 410 at the seller's own Prosper, Texas address and reviewed the seller's own website. It alleges that the pictured labels identify Fifty 410, suggesting it is the compounder of its semaglutide and tirzepatide products when it is not, and that a claim of clinically proven ingredients implies FDA approval. No close-out letter appears in the index. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 721481.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 721481, issued February 2026, to Aspen Aesthetics dba Fifty 410Pictured labels identify Fifty 410 as the compounder of semaglutide and tirzepatide products when it is not, and a claim of clinically proven ingredients implies the products are FDA-approved when they are not.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit Fifty 410

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.